Information Provided By: 
Fly News Breaks for July 24, 2019
MD
Jul 24, 2019 | 06:11 EDT
UBS analyst Whit Mayo lowered his price target on Mednax to $20 and kept his Sell rating, saying his proprietary data suggests that its intra-quarter trends are worsening with rising risks to the company's outlook for Q3 and the FY. The analyst believes that the current consensus estimates on Mednax may be "too optimistic", adding that in the absence of volume growth, the company's margins and earnings may continue to slide.
News For MD From the Last 2 Days
There are no results for your query MD
